Trial Outcomes & Findings for Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK) (NCT NCT01458587)

NCT ID: NCT01458587

Last Updated: 2013-03-14

Results Overview

Clearance rate for all lesions

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

70 participants

Primary outcome timeframe

Week 12

Results posted on

2013-03-14

Participant Flow

Recruitment period was from 28November2011 - 4April2012 at 3 medical clinics in the U.S.

Participant milestones

Participant milestones
Measure
Aminolevulinic Acid
ALA applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Vehicle
Vehicle applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Overall Study
STARTED
35
35
Overall Study
COMPLETED
34
35
Overall Study
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Aminolevulinic Acid
ALA applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Vehicle
Vehicle applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Overall Study
Withdrawal by Subject
1
0

Baseline Characteristics

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Aminolevulinic Acid
n=35 Participants
ALA applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Vehicle
n=35 Participants
Vehicle applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Total
n=70 Participants
Total of all reporting groups
Age Continuous
62.1 years
STANDARD_DEVIATION 9.96 • n=5 Participants
65.6 years
STANDARD_DEVIATION 9.30 • n=7 Participants
63.8 years
STANDARD_DEVIATION 9.72 • n=5 Participants
Sex: Female, Male
Female
13 Participants
n=5 Participants
12 Participants
n=7 Participants
25 Participants
n=5 Participants
Sex: Female, Male
Male
22 Participants
n=5 Participants
23 Participants
n=7 Participants
45 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
35 Participants
n=5 Participants
35 Participants
n=7 Participants
70 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
35 Participants
n=5 Participants
35 Participants
n=7 Participants
70 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
35 participants
n=5 Participants
35 participants
n=7 Participants
70 participants
n=5 Participants

PRIMARY outcome

Timeframe: Week 12

Population: ITT analysis with LOCF

Clearance rate for all lesions

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Lesion Clearance Rate
88.7 percentage of lesions cleared
Standard Deviation 25.1
70.0 percentage of lesions cleared
Standard Deviation 31.1
16.7 percentage of lesions cleared
Standard Deviation 27.6
5.6 percentage of lesions cleared
Standard Deviation 26.8

SECONDARY outcome

Timeframe: Week 8

Population: ITT LOCF

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Lesion Clearance Rate
75.0 percentage of lesions cleared
Standard Deviation 34.6
47.4 percentage of lesions cleared
Standard Deviation 30.7
3.3 percentage of lesions cleared
Standard Deviation 28.7
6.3 percentage of lesions cleared
Standard Deviation 25.8

SECONDARY outcome

Timeframe: Week 8

Population: ITT LOCF

proportion of subjects with a count of zero lesions in the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Complete Clearance Rate
8 arms 100% cleared
4 arms 100% cleared
0 arms 100% cleared
0 arms 100% cleared

SECONDARY outcome

Timeframe: Week 12

Population: ITT LOCF

proportion of subjects with a count of zero lesions in the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Complete Clearance Rate
12 arms 100% cleared
7 arms 100% cleared
0 arms 100% cleared
1 arms 100% cleared

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: ITT LOCF

proportion of subjects with 75% or more reduction in the AK count in the Treatment Area as compared to baseline.

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Partial Clearance Rate
18 arms >75% cleared
5 arms >75% cleared
1 arms >75% cleared
2 arms >75% cleared

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: ITT LOCF

proportion of subjects with 75% or more reduction in the AK count in the Treatment Area as compared to baseline.

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Partial Clearance Rate
21 arms >75% cleared
15 arms >75% cleared
3 arms >75% cleared
2 arms >75% cleared

SECONDARY outcome

Timeframe: Week 12

Population: ITT

Subject satisfaction score 1. = Excellent (very satisfied) 2. = Good (moderately satisfied) 3. = Fair (slightly satisfied) 4. = Poor (not satisfied at all)

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 arms
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 arms
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 arms
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 arms
Vehicle application on one extremity unoccluded during the incubation period.
Subject Satisfaction Score
Slightly satisfied
3 participants
8 participants
7 participants
9 participants
Subject Satisfaction Score
Very satisfied
13 participants
7 participants
3 participants
1 participants
Subject Satisfaction Score
Moderately satisfied
16 participants
14 participants
5 participants
5 participants
Subject Satisfaction Score
Not satisfied
3 participants
6 participants
20 participants
20 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hyperpigmentation at Baseline
Grade 0 (none)
5 participants
5 participants
1 participants
1 participants
Hyperpigmentation at Baseline
Grade 1 (light)
20 participants
19 participants
23 participants
23 participants
Hyperpigmentation at Baseline
Grade 2 (moderate - small)
9 participants
10 participants
8 participants
8 participants
Hyperpigmentation at Baseline
Grade 3 (moderate - moderate)
1 participants
1 participants
3 participants
3 participants

SECONDARY outcome

Timeframe: 2 weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA+OCC
n=34 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hyperpigmentation at Visit 3
Grade 0 (none)
4 participants
4 participants
1 participants
1 participants
Hyperpigmentation at Visit 3
Grade 1 (light)
19 participants
20 participants
21 participants
21 participants
Hyperpigmentation at Visit 3
Grade 2 (moderate - small)
9 participants
10 participants
10 participants
10 participants
Hyperpigmentation at Visit 3
Grade 3 (moderate - moderate)
2 participants
1 participants
3 participants
3 participants

SECONDARY outcome

Timeframe: 8 weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hyperpigmentation at Visit 4
Grade 0 (none)
2 participants
2 participants
0 participants
0 participants
Hyperpigmentation at Visit 4
Grade 1 (light)
24 participants
21 participants
19 participants
17 participants
Hyperpigmentation at Visit 4
Grade 2 (moderate - small)
8 participants
11 participants
11 participants
13 participants
Hyperpigmentation at Visit 4
Grade 3 (moderate - moderate)
1 participants
1 participants
4 participants
4 participants

SECONDARY outcome

Timeframe: 12 weeks after PDT #1

Population: ITT

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hyperpigmentation at Visit 5
Grade 0 (none)
2 participants
2 participants
0 participants
0 participants
Hyperpigmentation at Visit 5
Grade 1 (light)
25 participants
23 participants
20 participants
20 participants
Hyperpigmentation at Visit 5
Grade 2 (moderate - small)
6 participants
8 participants
11 participants
11 participants
Hyperpigmentation at Visit 5
Grade 3 (moderate - moderate)
0 participants
0 participants
4 participants
4 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hypopigmentation at Baseline
Grade 0 (none)
9 participants
9 participants
8 participants
8 participants
Hypopigmentation at Baseline
Grade 1 (light)
21 participants
21 participants
24 participants
24 participants
Hypopigmentation at Baseline
Grade 2 (moderate - small)
5 participants
5 participants
2 participants
2 participants
Hypopigmentation at Baseline
Grade 3 (moderate - moderate)
0 participants
0 participants
1 participants
1 participants

SECONDARY outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Outcome measures

Outcome measures
Measure
ALA+OCC
n=34 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hypopigmentation at Visit 3
Grade 0 (none)
10 participants
10 participants
7 participants
7 participants
Hypopigmentation at Visit 3
Grade 1 (light)
20 participants
20 participants
26 participants
26 participants
Hypopigmentation at Visit 3
Grade 2 (moderate - small)
4 participants
5 participants
1 participants
1 participants
Hypopigmentation at Visit 3
Grade 3 (moderate - moderate)
0 participants
0 participants
1 participants
1 participants

SECONDARY outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hypopigmentation at Visit 4
Grade 0 (none)
13 participants
10 participants
9 participants
9 participants
Hypopigmentation at Visit 4
Grade 1 (light)
18 participants
21 participants
23 participants
23 participants
Hypopigmentation at Visit 4
Grade 2 (moderate - small)
3 participants
4 participants
1 participants
1 participants
Hypopigmentation at Visit 4
Grade 3 (moderate - moderate)
1 participants
0 participants
1 participants
1 participants

SECONDARY outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Hypopigmentation at Visit 5
Grade 0 (none)
10 participants
8 participants
12 participants
11 participants
Hypopigmentation at Visit 5
Grade 1 (light)
22 participants
24 participants
21 participants
22 participants
Hypopigmentation at Visit 5
Grade 2 (moderate - small)
1 participants
1 participants
1 participants
1 participants
Hypopigmentation at Visit 5
Grade 3 (moderate - moderate)
0 participants
0 participants
1 participants
1 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Erythema at Baseline
Grade 1 (minimal)
16 participants
16 participants
13 participants
12 participants
Erythema at Baseline
Grade 2 (mild)
8 participants
9 participants
9 participants
10 participants
Erythema at Baseline
Grade 3 (moderate)
1 participants
0 participants
1 participants
1 participants
Erythema at Baseline
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants
Erythema at Baseline
Grade 0 (none)
10 participants
10 participants
12 participants
12 participants

SECONDARY outcome

Timeframe: 5 Minutes after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Erythema Post-Light Treatment
Grade 0 (none)
0 participants
0 participants
4 participants
4 participants
Erythema Post-Light Treatment
Grade 1 (minimal)
0 participants
4 participants
11 participants
15 participants
Erythema Post-Light Treatment
Grade 2 (mild)
7 participants
19 participants
17 participants
13 participants
Erythema Post-Light Treatment
Grade 3 (moderate)
21 participants
10 participants
3 participants
3 participants
Erythema Post-Light Treatment
Grade 4 (severe)
7 participants
2 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Erythema at Visit 3
Grade 0 (none)
0 participants
4 participants
10 participants
10 participants
Erythema at Visit 3
Grade 1 (minimal)
8 participants
14 participants
15 participants
14 participants
Erythema at Visit 3
Grade 2 (mild)
14 participants
15 participants
9 participants
10 participants
Erythema at Visit 3
Grade 3 (moderate)
12 participants
2 participants
1 participants
1 participants
Erythema at Visit 3
Grade 4 (severe)
1 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Erythema at Visit 4
Grade 0 (none)
7 participants
6 participants
10 participants
11 participants
Erythema at Visit 4
Grade 1 (minimal)
17 participants
20 participants
16 participants
15 participants
Erythema at Visit 4
Grade 2 (mild)
9 participants
9 participants
7 participants
7 participants
Erythema at Visit 4
Grade 3 (moderate)
2 participants
0 participants
1 participants
1 participants
Erythema at Visit 4
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Erythema at Visit 5
Grade 0 (none)
9 participants
7 participants
11 participants
12 participants
Erythema at Visit 5
Grade 1 (minimal)
7 participants
12 participants
14 participants
14 participants
Erythema at Visit 5
Grade 2 (mild)
16 participants
14 participants
10 participants
9 participants
Erythema at Visit 5
Grade 3 (moderate)
1 participants
0 participants
0 participants
0 participants
Erythema at Visit 5
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Edema at Baseline
Grade 2 (mild)
0 participants
0 participants
0 participants
0 participants
Edema at Baseline
Grade 0 (none)
35 participants
35 participants
35 participants
35 participants
Edema at Baseline
Grade 1 (minimal)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 5 Minutes after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Edema Post-Light Treatment
Grade 0 (none)
28 participants
33 participants
34 participants
34 participants
Edema Post-Light Treatment
Grade 1 (minimal)
5 participants
2 participants
1 participants
1 participants
Edema Post-Light Treatment
Grade 2 (mild)
2 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Edema at Visit 3
Grade 0 (none)
27 participants
34 participants
35 participants
35 participants
Edema at Visit 3
Grade 1 (minimal)
5 participants
1 participants
0 participants
0 participants
Edema at Visit 3
Grade 2 (mild)
3 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Edema at Visit 4
Grade 0 (none)
35 participants
35 participants
34 participants
34 participants
Edema at Visit 4
Grade 1 (minimal)
0 participants
0 participants
0 participants
0 participants
Edema at Visit 4
Grade 2 (mild)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Edema at Visit 5
Grade 0 (none)
33 participants
33 participants
35 participants
35 participants
Edema at Visit 5
Grade 1 (minimal)
0 participants
0 participants
0 participants
0 participants
Edema at Visit 5
Grade 2 (mild)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT, observed

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Stinging/Burning at Baseline
Grade 0 (none)
35 participants
35 participants
35 participants
35 participants
Stinging/Burning at Baseline
Grade 1 (mild)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Baseline
Grade 2 (moderate)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Baseline
Grade 3 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: During PDT #1

Population: ITT, observed

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Stinging/Burning During Light Treatment
Grade 0 (none)
0 participants
0 participants
29 participants
29 participants
Stinging/Burning During Light Treatment
Grade 1 (mild)
5 participants
20 participants
6 participants
6 participants
Stinging/Burning During Light Treatment
Grade 2 (moderate)
21 participants
12 participants
0 participants
0 participants
Stinging/Burning During Light Treatment
Grade 3 (severe)
9 participants
3 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 5 minutes after PDT #1

Population: ITT, observed

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Stinging/Burning Post Light Treatment
Grade 0 (none)
0 participants
2 participants
30 participants
33 participants
Stinging/Burning Post Light Treatment
Grade 1 (mild)
7 participants
22 participants
5 participants
2 participants
Stinging/Burning Post Light Treatment
Grade 2 (moderate)
21 participants
10 participants
0 participants
0 participants
Stinging/Burning Post Light Treatment
Grade 3 (severe)
7 participants
1 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 2 Weeks after PDT #1

Population: ITT, observed

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Stinging/Burning at Visit 3
Grade 0 (none)
31 participants
35 participants
35 participants
35 participants
Stinging/Burning at Visit 3
Grade 1 (mild)
4 participants
0 participants
0 participants
0 participants
Stinging/Burning at Visit 3
Grade 2 (moderate)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Visit 3
Grade 3 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT, observed

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Stinging/Burning at Visit 4
Grade 0 (none)
35 participants
35 participants
34 participants
34 participants
Stinging/Burning at Visit 4
Grade 1 (mild)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Visit 4
Grade 2 (moderate)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Visit 4
Grade 3 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT, observed

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Stinging/Burning at Visit 5
Grade 3 (severe)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Visit 5
Grade 0 (none)
33 participants
33 participants
35 participants
35 participants
Stinging/Burning at Visit 5
Grade 1 (mild)
0 participants
0 participants
0 participants
0 participants
Stinging/Burning at Visit 5
Grade 2 (moderate)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT observed

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Scaling and Dryness at Baseline
Grade 0 (none)
16 participants
16 participants
17 participants
17 participants
Scaling and Dryness at Baseline
Grade 1 (minimal)
15 participants
15 participants
13 participants
13 participants
Scaling and Dryness at Baseline
Grade 2 (mild)
2 participants
2 participants
4 participants
4 participants
Scaling and Dryness at Baseline
Grade 3 (moderate)
2 participants
2 participants
1 participants
1 participants
Scaling and Dryness at Baseline
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 2 Weeks Post PDT #1

Population: ITT observed

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Scaling and Dryness at Visit 3
Grade 0 (none)
3 participants
5 participants
10 participants
11 participants
Scaling and Dryness at Visit 3
Grade 1 (minimal)
5 participants
17 participants
20 participants
19 participants
Scaling and Dryness at Visit 3
Grade 2 (mild)
5 participants
10 participants
3 participants
3 participants
Scaling and Dryness at Visit 3
Grade 3 (moderate)
21 participants
3 participants
2 participants
2 participants
Scaling and Dryness at Visit 3
Grade 4 (severe)
1 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 8 Weeks Post PDT #1

Population: ITT observed

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Scaling and Dryness at Visit 4
Grade 0 (none)
16 participants
17 participants
14 participants
14 participants
Scaling and Dryness at Visit 4
Grade 1 (minimal)
14 participants
12 participants
14 participants
14 participants
Scaling and Dryness at Visit 4
Grade 2 (mild)
4 participants
5 participants
3 participants
3 participants
Scaling and Dryness at Visit 4
Grade 3 (moderate)
1 participants
1 participants
3 participants
3 participants
Scaling and Dryness at Visit 4
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 Weeks Post PDT #1

Population: ITT observed

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
Scaling and Dryness at Visit 5
Grade 2 (mild)
2 participants
2 participants
5 participants
5 participants
Scaling and Dryness at Visit 5
Grade 0 (none)
18 participants
17 participants
12 participants
12 participants
Scaling and Dryness at Visit 5
Grade 1 (minimal)
12 participants
13 participants
17 participants
17 participants
Scaling and Dryness at Visit 5
Grade 3 (moderate)
1 participants
1 participants
1 participants
1 participants
Scaling and Dryness at Visit 5
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Baseline

Population: ITT observed

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
OOZING/VESICULATION/CRUSTING at Baseline
Grade 0 (none)
35 participants
35 participants
35 participants
35 participants
OOZING/VESICULATION/CRUSTING at Baseline
Grade 1 (minimal)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Baseline
Grade 2 (mild)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Baseline
Grade 3 (moderate)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Baseline
Grade 4 (severe)
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Week 2 after PDT #1

Population: ITT observed

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
OOZING/VESICULATION/CRUSTING at Visit 3
Grade 0 (none)
33 participants
34 participants
34 participants
34 participants
OOZING/VESICULATION/CRUSTING at Visit 3
Grade 1 (minimal)
1 participants
0 participants
1 participants
1 participants
OOZING/VESICULATION/CRUSTING at Visit 3
Grade 2 (mild)
0 participants
1 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 3
Grade 3 (moderate)
1 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 3
0
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 8 Weeks after PDT #1

Population: ITT observed

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA+OCC
n=35 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=35 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=34 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=34 Participants
Vehicle application on one extremity unoccluded during the incubation period.
OOZING/VESICULATION/CRUSTING at Visit 4
Grade 0 (none)
35 participants
35 participants
34 participants
34 participants
OOZING/VESICULATION/CRUSTING at Visit 4
Grade 1 (minimal)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 4
Grade 2 (mild)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 4
Grade 3 (moderate)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 4
0
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 Weeks after PDT #1

Population: ITT observed

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Outcome measures

Outcome measures
Measure
ALA+OCC
n=33 Participants
ALA application on one extremity occluded with plastic wrap during the incubation period.
ALA-OCC
n=33 Participants
ALA application on one extremity unoccluded during the incubation period.
VEH+OCC
n=35 Participants
Vehicle application on one extremity occluded with plastic wrap during the incubation period.
VEH-OCC
n=35 Participants
Vehicle application on one extremity unoccluded during the incubation period.
OOZING/VESICULATION/CRUSTING at Visit 5
Grade 0 (none)
33 participants
32 participants
35 participants
35 participants
OOZING/VESICULATION/CRUSTING at Visit 5
Grade 1 (minimal)
0 participants
1 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 5
Grade 2 (mild)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 5
Grade 3 (moderate)
0 participants
0 participants
0 participants
0 participants
OOZING/VESICULATION/CRUSTING at Visit 5
0
0 participants
0 participants
0 participants
0 participants

Adverse Events

Aminolevulinic Acid

Serious events: 0 serious events
Other events: 17 other events
Deaths: 0 deaths

Vehicle

Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Aminolevulinic Acid
n=35 participants at risk
ALA applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Vehicle
n=35 participants at risk
Vehicle applied to both extremities; one extremity on each subject randomized to occlusion with plastic wrap during the incubation period.
Infections and infestations
Upper respiratory tract infection
5.7%
2/35 • Number of events 2
2.9%
1/35 • Number of events 1
Infections and infestations
Wound infection
0.00%
0/35
5.7%
2/35 • Number of events 2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
11.4%
4/35 • Number of events 5
0.00%
0/35
Skin and subcutaneous tissue disorders
Actinic keratosis
0.00%
0/35
5.7%
2/35 • Number of events 2
Skin and subcutaneous tissue disorders
Pain
25.7%
9/35 • Number of events 10
0.00%
0/35
Skin and subcutaneous tissue disorders
Itching
5.7%
2/35 • Number of events 2
0.00%
0/35
Skin and subcutaneous tissue disorders
Swelling
5.7%
2/35 • Number of events 2
0.00%
0/35

Additional Information

Anna Houlihan

DUSA Pharmaceuticals, Inc.

Phone: 9147608796

Results disclosure agreements

  • Principal investigator is a sponsor employee The first publication of results from multi-center trial will be made by the Sponsor. If publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 60 days before publication so that sponsor can review the publication for confidential information.
  • Publication restrictions are in place

Restriction type: OTHER